Status:
SUSPENDED
Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders
Lead Sponsor:
Innodem Neurosciences
Conditions:
Neurological Disorders
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate seve...
Eligibility Criteria
Inclusion
- Aged 18 years old and above
- A score of ≥ 26 on the Montreal Cognitive Assessment (MoCA)
- Able to provide informed consent
- Visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses, surgery etc are permitted).
Exclusion
- Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control.
- Evidence or history of significant neurological disorder (e.g. MS, PD, ALS, Dementia)
- Use of prescription drugs known to influence ocular motor visual function, such as benzodiazepines, antipsychotics, and anticonvulsants.
- Diagnosed with an active substance use disorder.
- History of stroke.
- Recent traumatic brain injury (within the last 6 months).
Key Trial Info
Start Date :
April 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 3 2024
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05212727
Start Date
April 15 2022
End Date
May 3 2024
Last Update
March 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Innodem Neurosciences
Montreal, Quebec, Canada, H2T 2A4